Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 16% w/w cream for topical use. It is employed in the photodynamic treatment of actinic keratosis and superficial basal cell carcinoma, primarily in adult patients with suitable skin lesions.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved dermatological agent. The company adheres to stringent quality standards and regulatory compliance to ensure product integrity across global markets.

Metvix is used in photodynamic therapy for precancerous and early skin cancers.

Actinic keratosis: clears dysplastic lesions and reduces risk of progression. Superficial basal cell carcinoma: achieves lesion remission through selective cytotoxicity. Field cancerisation (multiple actinic keratoses): enables treatment of widespread lesions in a single session.

Common Side Effects: - Pain at the treatment site during illumination. - Redness (erythema) of the applied area. - Swelling (edema) around the lesion. - Crusting or scaling of the treated skin.

Serious or Rare Side Effects: - Severe phototoxic reaction extending beyond the treated area. - Secondary infection of the treated skin. - Allergic contact dermatitis to the cream components.

Precautions should be observed to optimise safety and efficacy.

Patient selection: use in adults with diagnosed actinic keratosis or superficial basal cell carcinoma. Lesion assessment: ensure lesions are suitable for photodynamic therapy. Light exposure: avoid sun exposure on treated area for the recommended period after illumination. Adjunctive care: apply appropriate wound care post‑treatment to support healing. Contraindications: avoid in patients with porphyria or known hypersensitivity to the cream. Store at room temperature: keep in original container, protect from light and moisture.

Potential drug interactions must be considered.

Major Interactions (Avoid): - Systemic photosensitizers: concurrent use may increase phototoxic risk. - Porphyrinogenic drugs: may exacerbate photosensitivity.

Moderate Interactions (Monitor Closely): - Topical retinoids: may increase skin irritation. - Chemotherapy agents affecting skin healing. - Immunosuppressants: may reduce treatment efficacy.